A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Metabolomic approaches have begun to catalog the metabolic disturbances that accompany CKD, but whether metabolite alterations can predict future CKD is unknown. We performed liquid chromatography/mass spectrometry-based metabolite profiling on plasma from 1434 participants in the Framingham Heart Study (FHS) who did not have CKD at baseline. During the following 8 years, 123 individuals developed CKD, defined by an estimated GFR of <60 ml/min per 1.73 m(2). Numerous metabolites were associated with incident CKD, including 16 that achieved the Bonferroni-adjusted significance threshold of P≤0.00023. To explore how the human kidney modulates these metabolites, we profiled arterial and renal venous plasma from nine individuals. Nine metabolites that predicted CKD in the FHS cohort decreased more than creatinine across the renal circulation, suggesting that they may reflect non-GFR-dependent functions, such as renal metabolism and secretion. Urine isotope dilution studies identified citrulline and choline as markers of renal metabolism and kynurenic acid as a marker of renal secretion. In turn, these analytes remained associated with incident CKD in the FHS cohort, even after adjustment for eGFR, age, sex, diabetes, hypertension, and proteinuria at baseline. Addition of a multimarker metabolite panel to clinical variables significantly increased the c-statistic (0.77-0.83, P<0.0001); net reclassification improvement was 0.78 (95% confidence interval, 0.60 to 0.95; P<0.0001). Thus, the addition of metabolite profiling to clinical data may significantly improve the ability to predict whether an individual will develop CKD by identifying predictors of renal risk that are independent of estimated GFR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent untargeted metabolomic study from the Framingham Heart Study among subjects with normal renal function identified elevated choline and TMAO levels at baseline were each associated with an increased future risk of developing CKD 33.”
In the citing paper
“Exciting new metabolomics data from the Framingham Heart Study indicated that TMAO was one of the few metabolites in the plasma of healthy subjects whose levels predicted incident development of CKD (58).”
From The contributory role of gut microbiota in cardiovascular disease (2014) · cites this paper as [58]
In the citing paper
“Patients with poor kidney function have elevated plasma TMAO concentrations (93,109).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [93]
In the citing paper
“In 123 individuals (out of 1,434 participants) in the Framingham Heart Study who did not have CKD at baseline but developed it during eight years of follow-up, metabolomic profiling on plasma showed that TMAO was associated with incident CKD even after adjustment for GFR, sex, diabetes, hypertension, and proteinuria at baseline (93).”
From Trimethylamine N -Oxide, the Microbiome, and Heart and Kidney Disease (2017) · cites this paper as [93]
In the citing paper
“Subsequent studies showed that TMAO is rapidly cleared from the body after ingestion157,165,191.”
From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [191]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 39 · Cited by 307
Metadata
- Authors
- Rhee, E. P., Clish, C. B., Ghorbani, A., Larson, M. G., Elmariah, S., McCabe, E., Yang, Q., Cheng, S., Pierce, K., Deik, A., Souza, A. L., Farrell, L., Domos, C., Yeh, R. W., Palacios, I., Rosenfield, K., Vasan, R. S., Florez, J. C., Wang, T. J., Fox, C. S., & Gerszten, R. E.
- Affiliations
- Broad Institute (US)
- Boston University (US)
- Corresponding author
- Rhee, Eugene P.
- Cheng, Susan
- Fox, Caroline S.
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2013-08
- Volume
- 24
- Issue
- 8
- Pages
- 1330-1338
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC3736702
- OpenAlex
- W2098397904
- Cited by
- 307
- References
- 39
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 22 · 2023: 36 · 2022: 29 · 2021: 27 · 2020: 30 · 2019: 28 · 2018: 22 · 2017: 23 · 2016: 17 · 2015: 19 · 2014: 11 · 2013: 5
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (n01hc25195-41-0-1)
- National Heart, Lung, and Blood Institute (N01‐HC25195, R01HL081572, N01-HC-025195)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK090142, R01-DK-HL-081572)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- chronic kidney disease, CKD prediction, plasma metabolites, metabolite profiling, renal metabolism, renal secretion, citrulline, choline, kynurenic acid, multimarker panels, risk reclassification, Framingham Heart Study
- MeSH terms
- Aged, Chromatography, Liquid, Female, Follow-Up Studies, Humans, Kidney Failure, Chronic, Kidney Function Tests, Male, Middle Aged, Prospective Studies, Risk Factors, Mass Spectrometry, Biomarkers, Incidence, Metabolomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction. https://app.cochat.ai/papers/10.1681/asn.2012101006
- The paper
- Rhee, E. P., Clish, C. B., Ghorbani, A., Larson, M. G., Elmariah, S., McCabe, E., Yang, Q., Cheng, S., Pierce, K., Deik, A., Souza, A. L., Farrell, L., Domos, C., Yeh, R. W., Palacios, I., Rosenfield, K., Vasan, R. S., Florez, J. C., Wang, T. J., . . . Gerszten, R. E. (2013). A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2012101006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.